BRAF and non-small cell lung carcinoma: Previous studies revealed that dabrafenib plus trametinib have shown substantial antitumor activity in patients with previously treated BRAF-V600E mutated metastatic NSCLC and untreated BRAFV-600E mutated NSCLC (50, 51).